154 related articles for article (PubMed ID: 26464623)
1. Role of midkine-progranulin interaction during angiogenesis of hepatocellular carcinoma.
Huang H; Li J; Lu Y; Min L; Li D; Dai L
Int J Clin Exp Pathol; 2015; 8(8):8809-20. PubMed ID: 26464623
[TBL] [Abstract][Full Text] [Related]
2. Novel functional proteins interact with midkine in hepatic cancer cells.
Yan Q; Huang HL; Yao X; Li J; Li LQ; Zhong J; Min LS; Dai LC; Zheng SS
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):272-7. PubMed ID: 22672821
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma.
Shih TC; Tien YJ; Wen CJ; Yeh TS; Yu MC; Huang CH; Lee YS; Yen TC; Hsieh SY
J Hepatol; 2012 Sep; 57(3):584-91. PubMed ID: 22613005
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.
Dai LC; Wang X; Yao X; Lu YL; Ping JL; He JF
World J Gastroenterol; 2007 Feb; 13(8):1208-13. PubMed ID: 17451201
[TBL] [Abstract][Full Text] [Related]
5. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer.
Rawnaq T; Dietrich L; Wolters-Eisfeld G; Uzunoglu FG; Vashist YK; Bachmann K; Simon R; Izbicki JR; Bockhorn M; Güngör C
Mol Cancer Res; 2014 May; 12(5):670-80. PubMed ID: 24567526
[TBL] [Abstract][Full Text] [Related]
6. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-induced angiogenesis in human hepatocellular carcinoma.
Kim KR; Moon HE; Kim KW
J Mol Med (Berl); 2002 Nov; 80(11):703-14. PubMed ID: 12436347
[TBL] [Abstract][Full Text] [Related]
8. Phospholipid Scramblase 1 Interacts with Midkine and Regulates Hepatic Cancer Cell Proliferation and Migration.
Huang H; Lu Y; Min L; Jiang P; Dai L
Clin Lab; 2015; 61(10):1501-8. PubMed ID: 26642712
[TBL] [Abstract][Full Text] [Related]
9. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
10. The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding.
De Muynck L; Herdewyn S; Beel S; Scheveneels W; Van Den Bosch L; Robberecht W; Van Damme P
Neurobiol Aging; 2013 Nov; 34(11):2541-7. PubMed ID: 23706646
[TBL] [Abstract][Full Text] [Related]
11. Midkine mediates dysfunction of liver sinusoidal endothelial cells through integrin α4 and α6.
Wu L; Chen H; Fu C; Xing M; Fang H; Yang F; Yang Q; Zhang Y; Li W; Chen Z
Vascul Pharmacol; 2022 Dec; 147():107113. PubMed ID: 36184060
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
[TBL] [Abstract][Full Text] [Related]
13. Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells.
Eguchi R; Nakano T; Wakabayashi I
Oncogene; 2017 Feb; 36(5):714-722. PubMed ID: 27345409
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines.
Lasagna N; Fantappiè O; Solazzo M; Morbidelli L; Marchetti S; Cipriani G; Ziche M; Mazzanti R
Cancer Res; 2006 Mar; 66(5):2673-82. PubMed ID: 16510587
[TBL] [Abstract][Full Text] [Related]
15. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma.
Xue X; Gao W; Sun B; Xu Y; Han B; Wang F; Zhang Y; Sun J; Wei J; Lu Z; Zhu Y; Sato Y; Sekido Y; Miao Y; Kondo Y
Oncogene; 2013 Mar; 32(13):1724-34. PubMed ID: 22614011
[TBL] [Abstract][Full Text] [Related]
16. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
Zhao X; Li J; Zhuo J; Cai L
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
[TBL] [Abstract][Full Text] [Related]
17. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
18. Shedding more light on the role of Midkine in hepatocellular carcinoma: New perspectives on diagnosis and therapy.
Gowhari Shabgah A; Ezzatifar F; Aravindhan S; Olegovna Zekiy A; Ahmadi M; Gheibihayat SM; Gholizadeh Navashenaq J
IUBMB Life; 2021 Apr; 73(4):659-669. PubMed ID: 33625758
[TBL] [Abstract][Full Text] [Related]
19. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
20. Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.
Zhao J; Lin W; Zhuang Q; Zhong X; Cao Z; Hong Z; Peng J
Integr Cancer Ther; 2014 Nov; 13(6):520-8. PubMed ID: 25148840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
